A Phase 3 interventional study of Abiraterone acetate and Prednisone in Metastatic Castration-resistant Prostate Cancer and Metastatic Breast Cancer, sponsored by Janssen Research & Development, LLC. Completed at 22 sites in 7 countries. Per ClinicalTrials.gov, last updated 2022-05-10.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Breast Neoplasms by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Johnson & Johnson.
Among the 19 studies in Breast Neoplasms by Johnson & Johnson, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 3, and was the 14th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 19 studies in Breast Neoplasms by Johnson & Johnson is open now, in 2 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Australia
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 114 across the 18 interventional studies, 500 across the 1 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Breast Neoplasms by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04829604Ambrx, Inc.ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Breast Neoplasms by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
This is a nonrandomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), long-term safety follow-up study of abiraterone acetate in approximately 300 patients from other completed abiraterone acetate clinical studies. Patients must have received at least 3 months of treatment with abiraterone acetate and a low-dose corticosteroid and, based on investigator assessment, may benefit from continued treatment. This study will consist of a screening period followed by open-label treatment of continued abiraterone acetate access. The patients will continue with the same abiraterone acetate and low-dose corticosteroid dosing regimen they were receiving in the previous abiraterone acetate clinical study until the investigator determines that the patient is no longer receiving benefit or the sponsor terminates the study. Patients can be withdrawn from the study if an alternative access (eg, patient-assistance program or commercial source of abiraterone acetate) is available and feasible. Each cycle of treatment will be 28 days. Investigators will monitor and assess the patients for response to treatment or progression according to routine practice or as clinically indicated to determine whether continued treatment with abiraterone acetate is warranted. No efficacy data are being collected. Safety will be monitored throughout the study for a maximum duration of 9 years. End-of-study assessments will be performed at least 30 days after the last dose of abiraterone or upon early withdrawal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
Drug: Abiraterone acetate · Drug: Prednisone
Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
Number of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.
Time frame: Up to 9 years
| Milestone | Abiraterone Acetate + Prednisone/Prednisolone |
|---|---|
| Started | 31 |
| Completed | 30 |
| Not completed | 1 |
| Withdrew: Death | 1 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event.
| Participants | Abiraterone Acetate + Prednisone/Prednisolone |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 16 |
Collected over Up to 9 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone Acetate + Prednisone/Prednisolone | 1/31 (3.2%) | 16/31 (51.6%) | 0/31 (0%) |
| Event | Abiraterone Acetate + Prednisone/Prednisolone |
|---|---|
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 3/31 |
| DiarrhoeaGastrointestinal disorders | 2/31 |
| FallInjury, poisoning and procedural complications | 2/31 |
| Skin LacerationInjury, poisoning and procedural complications | 2/31 |
| Lower Respiratory Tract InfectionInfections and infestations | 1/31 |
| Urinary Tract InfectionInfections and infestations | 1/31 |
| DehydrationMetabolism and nutrition disorders | 1/31 |
| Cerebrovascular AccidentNervous system disorders | 1/31 |
| EncephalopathyNervous system disorders | 1/31 |
| Spinal Cord CompressionNervous system disorders | 1/31 |
| Event | Abiraterone Acetate + Prednisone/Prednisolone |
|---|---|
| Lower Respiratory Tract InfectionInfections and infestations | 0/31 |
| Urinary Tract InfectionInfections and infestations | 0/31 |
| DehydrationMetabolism and nutrition disorders | 0/31 |
| Cerebrovascular AccidentNervous system disorders | 0/31 |
| EncephalopathyNervous system disorders | 0/31 |
| Spinal Cord CompressionNervous system disorders | 0/31 |
| SyncopeNervous system disorders | 0/31 |
| Cardiac FailureCardiac disorders | 0/31 |
| Cardiac Failure CongestiveCardiac disorders | 0/31 |
| Myocardial InfarctionCardiac disorders | 0/31 |
| Age, Customized(Participants) | Abiraterone Acetate + Prednisone/Prednisolone |
|---|---|
| 63-90 years | 31 |
| Sex: Female, Male(Participants) | Abiraterone Acetate + Prednisone/Prednisolone |
|---|---|
| Female | 0 |
| Male | 31 |
| Race and Ethnicity Not Collected(Participants) | Abiraterone Acetate + Prednisone/Prednisolone |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2012 to primary completion in Apr 2021, 108 months.
Results were first posted in May 2022, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 108 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate
Janssen Research & Development, LLC →